Patents Examined by Nirmaz S. Basi
  • Patent number: 6528482
    Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: March 4, 2003
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent Galibert, Eugene Maraskovsky, William C. Dougall
  • Patent number: 6143871
    Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R.alpha. can be used in medicine, in diagnosis and in screening for agonists/antagonists of IL-13/IL-4. One such polypeptide is shown in FIG. 1.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: November 7, 2000
    Inventors: Jean-Yves Bonnefoy, Jean-Fran.cedilla.ois Gauchat
  • Patent number: 6117977
    Abstract: The invention concerns novel members of the endocytic type C lectin family and methods and means for producing them. The native polypeptides of the invention are characterized by containing a signal sequence, a cysteine rich domain, a fibronectin type II domain, 8 type C lectin domains, a transmembrane domain and a cytoplasmic domain. Nucleotide sequences encoding such polypeptides, vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel type C lectins are also within the scope of the invention.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: September 12, 2000
    Assignee: Genentech, Inc.
    Inventors: Laurence A. Lasky, Kai Wu
  • Patent number: 6008338
    Abstract: An isolated DNA molecule encodes a photoreceptive retinaldehyde-binding protein of the visual system and brain. The isolated protein is a putative receptor for an all-trans-retinylidene chromophore that absorbs light in the visible range. Antibodies are disclosed which specifically bind to such retinaldehyde binding protein. An altered retinaldehyde binding protein with a 38 amino acid deletion is an indicator of abnormality in the retinal pigment epithelium. Antibodies are also disclosed which are specific to the altered retinaldehyde binding protein.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: December 28, 1999
    Inventor: Henry K.W. Fong